A Transcription Factor Map as Revealed by a Genome- Wide Gene Expression Analysis of Whole-Blood mRNA Transcriptome in Multiple Sclerosis

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Riveros, Carlos ^a   Mellor, Drew ^a,h   Gandhi, Kaushal S ^c   Mckay, Fiona C ^c   Cox, Mathew B ^a,f   Berretta, Regina ^a   Vaezpour, S Yahya ^a,g   Inostroza Ponta, Mario ^a,i   Broadley, Simon A ^d,e   Heard, Robert N ^c   Vucic, Stephen ^c   Stewart, Graeme J ^c   Williams, David W ^a   Scott, Rodney J ^a   Lechner Scott, Jeanette ^a   Booth, David R ^c   Moscato, Pablo ^a,b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b Australian Government Australian Research Council   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d GRIFFITH UNIVERSITY   (Australia)

^e GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^f HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^g AMIRKABIR UNIVERSITY OF TECHNOLOGY   (Iran)

^h UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

ⁱ UNIVERSIDAD DE SANTIAGO DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR; ACTIVATING TRANSCRIPTION FACTOR 2; EARLY GROWTH RESPONSE FACTOR; MESSENGER RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F4; TRANSCRIPTION FACTOR SOX5; TRANSCRIPTION FACTOR YY1; TRANSCRIPTOME;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE MAPPING; GENETIC ASSOCIATION; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHENOTYPE; T LYMPHOCYTE; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; TRANSLATION INITIATION; UPREGULATION; AGED; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; CYTOLOGY; METABOLISM; MIDDLE AGED; OLIGODENDROGLIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 78649928621     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014176     Document Type: Article

References (285)

1. Compston A, McDonald I, Noseworthy J, Lassmann H, Miller D, et al. (2005) McAlpine's multiple sclerosis: Churchill Livingstone Elsevier: Philadelphia.
2. Hauser SL, Oksenberg JR (2006) The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration. 52: 61-76.
3. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, et al. (2007) How common are the ''common'' neurologic disorders? Neurology 68: 326-337.
4. Pugliatti M, Harbo HF, Holmoy T, Kampman MT, Myhr KM, et al. (2008) Environmental risk factors in multiple sclerosis. Acta Neurol Scand Suppl 188: 34-40.
5. Ramagopalan SV, Dyment DA, Ebers GC (2008) Genetic epidemiology: the use of old and new tools for multiple sclerosis. Trends Neurosci 31: 645-652.
6. Ebers GC (2008) Environmental factors and multiple sclerosis. Lancet Neurol 7: 268-277.
7. Hawkes C, Macgregor A (2009) Twin studies and the heritability of MS: a conclusion. Multiple Sclerosis 15: 661-667.
8. Smestad C, Sandvik L, Holmoy T, Harbo HF, Celius EG (2008) Marked differences in prevalence of multiple sclerosis between ethnic groups in Oslo, Norway. J Neurol 255: 49-55.
9. Rosati G (2001) The prevalence of multiple sclerosis in the world: an update. Neurological Sciences 22: 117-139.
10. Alter M, Kahana E, Zilber N, Miller A, for the Israeli MS Study Group (2006) Multiple sclerosis frequency in Israel's diverse populations. Neurology 66: 1061-1066.
11. Svejgaard A (2008) The immunogenetics of multiple sclerosis. Immunogenetics 60: 275-286.
12. The International Multiple Sclerosis Genetics Consortium (2007) Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study. N Engl J Med 357: 851-862.
13. Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, et al. (2007) Interleukin 7 receptor [alpha] chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 39: 1083-1091.
14. Rubio JP, Stankovich J, Field J, Tubridy N, Marriott M, et al. (2008) Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians. Genes Immun 9: 624-630.
15. Akkad DA, Hoffjan S, Petrasch-Parwez E, Beygo J, Gold R, et al. (2009) Variation in the IL7RA and IL2RA genes in German multiple sclerosis patients. Journal of Autoimmunity 32: 110-115.
16. Ramagopalan SV, Anderson C, Sadovnick AD, Ebers GC, Matesanz F, et al. (2007) Genomewide Study of Multiple Sclerosis. N Engl J Med 357: 2199-2201.
17. International Multiple Sclerosis Genetics Consortium (2008) The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes Immun 10: 11-14.
18. Aulchenko YS, Hoppenbrouwers IA, Ramagopalan SV, Broer L, Jafari N, et al. (2008) Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat Genet 40: 1402-1403.
19. Ban M, Goris A, Lorentzen AR, Baker A, Mihalova T, et al. (2009) Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur J Hum Genet.
20. De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, et al. (2009) Meta- analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 41: 776-782.
21. The Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene) (2009) Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet 41: 824-828.
22. Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, et al. (2009) Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 18: 767-778.
23. Brynedal B, Bomfim IL, Olsson T, Duvefelt K, Hillert J (2009) Differential expression, and genetic association, of CD58 in Swedish multiple sclerosis patients. Proceedings of the National Academy of Sciences 106: E58-E58.
24. Hillert J, Gronnig M, Nyland H, Link H, Olerup O (1992) An immunogenetic heterogeneity in multiple sclerosis. J Neurol Neurosurg Psychiatry 55: 887-890.
25. Olerup O, Hillert J, Fredrikson S, Olsson T, Kam-Hansen S, et al. (1989) Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci USA 86: 7113-7117.
26. Francis D, Thompson A, Brookes P, Davey N, Lechler R, et al. (1991) Multiple sclerosis and HLA: is the susceptibility gene really HLA-DR or -DQ? Human immunology 32: 119-124.
27. Dermitzakis ET (2008) From gene expression to disease risk. Nat Genet 40: 492-493.
28. Gandhi KS, McKay FC, Cox M, Riveros C, Armstrong N, et al. The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Hum Mol Genet.
29. Eggert M, Kluter A, Zettl UK, Neeck G (2006) Transcription Factors in Autoimmune Diseases. Frontiers in Medicinal Chemistry 3: 383-397.
30. Peng SL (2008) Transcription factors in autoimmune diseases. Front Biosci 13: 4218-4240.
31. Li H, Lu Y, Smith HK, Richardson WD (2007) Olig1 and Sox10 interact synergistically to drive myelin basic protein transcription in oligodendrocytes. J Neurosci 27: 14375-14382.
32. O'Connor RA, Anderton SM (2008) Foxp3+ regulatory T cells in the control of experimental CNS autoimmune disease. J Neuroimmunol 193: 1-11.
33. Zaheer S, Wu Y, Bassett J, Yang B, Zaheer A (2007) Glia maturation factor regulation of STAT expression: a novel mechanism in experimental autoimmune encephalomyelitis. Neurochem Res 32: 2123-2131.
34. Chavanas S, Adoue V, Mechin MC, Ying S, Dong S, et al. (2008) Long-range enhancer associated with chromatin looping allows AP-1 regulation of the peptidylarginine deiminase 3 gene in differentiated keratinocyte. PLoS ONE 3: e3408.
35. Christophi GP, Hudson CA, Gruber RC, Christophi CP, Mihai C, et al. (2008) SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients. Lab Invest 88: 243-255.
36. Kuipers HF, Biesta PJ, Montagne LJ, van Haastert ES, van der Valk P, et al. (2008) CC chemokine receptor 5 gene promoter activation by the cyclic AMP response element binding transcription factor. Blood 112: 1610-1619.
37. Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S, Inoges S, Lopez- Diaz de Cerio A, et al. (2008) IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol 38: 576-586.
38. Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, et al. (2007) Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 8: 74-83.
39. Rodriguez M, Zoecklein L, Gamez JD, Pavelko KD, Papke LM, et al. (2006) STAT4- and STAT6-signaling molecules in a murine model of multiple sclerosis. FASEB J 20: 343-345.
40. Qin H, Wilson CA, Lee SJ, Zhao X, Benveniste EN (2005) LPS induces CD40 gene expression through the activation of NF-kappaB and STAT-1alpha in macrophages and microglia. Blood 106: 3114-3122.
41. Flores N, Duran C, Blasco MR, Puerta C, Dorado B, et al. (2003) NFkappaB and AP-1 DNA binding activity in patients with multiple sclerosis. J Neuroimmunol 135: 141-147.
42. Miterski B, Bohringer S, Klein W, Sindern E, Haupts M, et al. (2002) Inhibitors in the NFkappaB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations. Genes Immun 3: 211-219.
43. Kim MO, Si Q, Zhou JN, Pestell RG, Brosnan CF, et al. (2002) Interferon-beta activates multiple signaling cascades in primary human microglia. J Neurochem 81: 1361-1371.
44. Huang CJ, Nazarian R, Lee J, Zhao PM, Espinosa-Jeffrey A, et al. (2002) Tumor necrosis factor modulates transcription of myelin basic protein gene through nuclear factor kappa B in a human oligodendroglioma cell line. Int J Dev Neurosci 20: 289-296.
45. Feng X, Petraglia AL, Chen M, Byskosh PV, Boos MD, et al. (2002) Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol 129: 205-215.
46. Gobin SJ, Montagne L, Van Zutphen M, Van Der Valk P, Van Den Elsen PJ, et al. (2001) Upregulation of transcription factors controlling MHC expression in multiple sclerosis lesions. Glia 36: 68-77.
47. Colombatti M, Moretto G, Tommasi M, Fiorini E, Poffe O, et al. (2001) Human MBP-specific T cells regulate IL-6 gene expression in astrocytes through cell-cell contacts and soluble factors. Glia 35: 224-233.
48. Azimi N, Mariner J, Jacobson S, Waldmann TA (2000) How does interleukin 15 contribute to the pathogenesis of HTLV type 1-associated myelopathy/ tropical spastic paraparesis? AIDS Res Hum Retroviruses 16: 1717-1722.
49. Hilliard B, Samoilova EB, Liu TS, Rostami A, Chen Y (1999) Experimental autoimmune encephalomyelitis in NF-kappa B-deficient mice: roles of NF- kappa B in the activation and differentiation of autoreactive T cells. J Immunol 163: 2937-2943.
50. Bonetti B, Stegagno C, Cannella B, Rizzuto N, Moretto G, et al. (1999) Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology. Am J Pathol 155: 1433-1438.
51. Weinstock-Guttman B, Bhasi K, Badgett D, Tamano-Blanco M, Minhas M, et al. (2008) Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients. J Neuroimmunol 205: 113-125.
52. Frisullo G, Nociti V, Iorio R, Patanella AK, Marti A, et al. (2008) The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis. J Neuroimmunol 205: 126-134.
53. Satoh J, Misawa T, Tabunoki H, Yamamura T (2008) Molecular network analysis of T-cell transcriptome suggests aberrant regulation of gene expression by NF-kappaB as a biomarker for relapse of multiple sclerosis. Dis Markers 25: 27-35.
54. Martinez A, Varade J, Marquez A, Cenit MC, Espino L, et al. (2008) Association of the STAT4 gene with increased susceptibility for some immune- mediated diseases. Arthritis Rheum 58: 2598-2602.
55. Liu X, Lee YS, Yu CR, Egwuagu CE (2008) Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases. J Immunol 180: 6070-6076.
56. Zeis T, Graumann U, Reynolds R, Schaeren-Wiemers N (2008) Normal- appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain 131: 288-303.
57. Fortunato G, Calcagno G, Bresciamorra V, Salvatore E, Filla A, et al. (2008) Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res 28: 141-152.
58. Taki S (2002) Type I interferons and autoimmunity: lessons from the clinic and from IRF-2-deficient mice. Cytokine Growth Factor Rev 13: 379-391.
59. Kristjansdottir G, Sandling JK, Bonetti A, Roos IM, Milani L, et al. (2008) Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet 45: 362-369.
60. Klotz L, Schmidt S, Heun R, Klockgether T, Kolsch H (2009) Association of the PPARgamma gene polymorphism Pro12Ala with delayed onset of multiple sclerosis. Neurosci Lett 449: 81-83.
61. Bright JJ, Walline CC, Kanakasabai S, Chakraborty S (2008) Targeting PPAR as a therapy to treat multiple sclerosis. Expert Opin Ther Targets 12: 1565-1575.
62. Schmidt S, Moric E, Schmidt M, Sastre M, Feinstein DL, et al. (2004) Anti- inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J Leukoc Biol 75: 478-485.
63. Mrak RE, Landreth GE (2004) PPARgamma, neuroinflammation, and disease. J Neuroinflammation 1: 5.
64. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, et al. (2004) Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol 172: 5790-5798.
65. Feinstein DL (2003) Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol Ther 5: 67-73.
66. O'Keefe GM, Nguyen VT, Benveniste EN (2002) Regulation and function of class II major histocompatibility complex, CD40, and B7 expression in macrophages and microglia: Implications in neurological diseases. J Neurovirol 8: 496-512.
67. Nguyen VT, Benveniste EN (2002) Critical role of tumor necrosis factor-alpha and NF-kappa B in interferon-gamma -induced CD40 expression in microglia/ macrophages. J Biol Chem 277: 13796-13803.
68. Diab A, Deng C, Smith JD, Hussain RZ, Phanavanh B, et al. (2002) Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta (12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalo- myelitis. J Immunol 168: 2508-2515.
69. Grekova MC, Salerno K, Mikkilineni R, Richert JR (2002) Sp3 expression in immune cells: a quantitative study. Lab Invest 82: 1131-1138.
70. Grekova MC, Scherer SW, Trabb J, Richert JR (2000) Localization of the human SP3 gene to chromosome 7p14-p15.2. The lack of expression in multiple sclerosis does not reflect abnormal gene organization. J Neuroimmunol 106: 214-219.
71. Grekova MC, Robinson ED, Faerber MA, Katz P, McFarland HF, et al. (1996) Deficient expression in multiple sclerosis of the inhibitory transcription factor Sp3 in mononuclear blood cells. Ann Neurol 40: 108-112.
72. Montes M, Zhang X, Berthelot L, Laplaud DA, Brouard S, et al. (2009) Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells. Clin Immunol 130: 133-144.
73. Avasarala JR, Chittur SV, George AD, Tine JA (2008) Microarray analysis in B cells among siblings with/without MS - role for transcription factor TCF2. BMC Med Genomics 1: 2.
74. Gerhauser I, Alldinger S, Baumgartner W (2007) Ets-1 represents a pivotal transcription factor for viral clearance, inflammation, and demyelination in a mouse model of multiple sclerosis. J Neuroimmunol 188: 86-94.
75. Venken K, Hellings N, Hensen K, Rummens JL, Medaer R, et al. (2006) Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J Neurosci Res 83: 1432-1446.
76. McKay FC, Swain LI, Schibeci SD, Rubio JP, Kilpatrick TJ, et al. (2008) CD127 immunophenotyping suggests altered CD4+ T cell regulation in primary progressive multiple sclerosis. J Autoimmun 31: 52-58.
77. Stenner MP, Waschbisch A, Buck D, Doerck S, Einsele H, et al. (2008) Effects of natalizumab treatment on Foxp3+ T regulatory cells. PLoS ONE 3: e3319.
78. Awasthi A, Murugaiyan G, Kuchroo VK (2008) Interplay between effector Th17 and regulatory T cells. J Clin Immunol 28: 660-670.
79. Aranami T, Yamamura T (2008) Th17 Cells and autoimmune encephalomy- elitis (EAE/MS). Allergol Int 57: 115-120.
80. Feger U, Luther C, Poeschel S, Melms A, Tolosa E, et al. (2007) Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin Exp Immunol 147: 412-418.
81. Kumar M, Putzki N, Limmroth V, Remus R, Lindemann M, et al. (2006) CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein- induced proliferation in patients with multiple sclerosis. J Neuroimmunol 180: 178-184.
82. Hong J, Zang YC, Nie H, Zhang JZ (2006) CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis. Proc Natl Acad Sci U S A 103: 5024-5029.
83. Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, et al. (2005) Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 81: 45-52.
84. Hong J, Li N, Zhang X, Zheng B, Zhang JZ (2005) Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci U S A 102: 6449-6454.
85. Frisullo G, Nociti V, Iorio R, Patanella AK, Caggiula M, et al. (2009) Regulatory T cells fail to suppress CD4T+-bet+ T cells in relapsing multiple sclerosis patients. Immunology 127: 418-428.
86. Rollins B, Martin MV, Morgan L, Vawter MP (2010) Analysis of whole genome biomarker expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 153B: 919-936.
87. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
88. Fayyad UM, Irani KB (1993) Multi-Interval Discretization of Continuous- Valued Attributes for Classification Learning. INTERNATIONAL JOINT CONFERENCE ON ARTIFICIAL INTELLIGENCE.
89. Berretta R, Costa W, Moscato P (2008) Combinatorial optimization models for finding genetic signatures from gene expression datasets. Methods Mol Biol 453: 363-377.
90. Rosso OA, Mendes A, Berretta R, Rostas JA, Hunter M, et al. (2009) Distinguishing childhood absence epilepsy patients from controls by the analysis of their background brain electrical activity (II): a combinatorial optimization approach for electrode selection. J Neurosci Methods 181: 257-267.
91. Gomez Ravetti M, Moscato P (2008) Identification of a 5-protein biomarker molecular signature for predicting Alzheimer's disease. PLoS ONE 3: e3111.
92. Hourani M, Berretta R, Mendes A, Moscato P (2008) Genetic signatures for a rodent model of Parkinson's disease using combinatorial optimization methods. Methods Mol Biol 453: 379-392.
93. Mendes A, Scott RJ, Moscato P (2008) Microarrays-identifying molecular portraits for prostate tumors with different Gleason patterns. Methods Mol Med 141: 131-151.
94. Johnstone D, Riveros C, Moscato P, Milward L (2008) Effects of different normalisation and analysis procedures on illumina gene expression microarray data. Proceedings of the 19th International Conference on Genome Informatics (GIW 2008).
95. Chang JT, Nevins JR (2006) GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 22: 2926-2933.
96. Ban EM, LeBoeuf RD (1994) Suppressin: an endogenous negative regulator of immune cell activation. Immunol Res 13: 1-9.
97. Gardner JM, Anderson MS (2009) The sickness unto Deaf. Nat Immunol 10: 934-936.
98. Yip L, Su L, Sheng D, Chang P, Atkinson M, et al. (2009) Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes. Nat Immunol 10: 1026-1033.
99. Benjamins JA, Nedelkoska L, George EB (2003) Protection of mature oligodendrocytes by inhibitors of caspases and calpains. Neurochem Res 28: 143-152.
100. Della Chiesa M, Romeo E, Falco M, Balsamo M, Augugliaro R, et al. (2008) Evidence that the KIR2DS5 gene codes for a surface receptor triggering natural killer cell function. Eur J Immunol 38: 2284-2289.
101. Schellekens J, Rozemuller EH, Petersen EJ, van den Tweel JG, Verdonck LF, et al. (2008) Activating KIRs exert a crucial role on relapse and overall survival after HLA-identical sibling transplantation. Mol Immunol 45: 2255-2261.
102. Lorentzen AR, Karlsen TH, Olsson M, Smestad C, Mero IL, et al. (2009) Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis. Ann Neurol 65: 658-666.
103. Caserta S, Zamoyska R (2007) Memories are made of this: synergy of T cell receptor and cytokine signals in CD4(+) central memory cell survival. Trends Immunol 28: 245-248.
104. Dabrowska A, Kim N, Aldovini A (2008) Tat-induced FOXO3a is a key mediator of apoptosis in HIV-1-infected human CD4+ T lymphocytes. J Immunol 181: 8460-8477.
105. van Grevenynghe J, Procopio FA, He Z, Chomont N, Riou C, et al. (2008) Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection. Nat Med 14: 266-274.
106. Riou C, Yassine-Diab B, Van grevenynghe J, Somogyi R, Greller LD, et al. (2007) Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells. J Exp Med 204: 79-91.
107. Lin L, Hron JD, Peng SL (2004) Regulation of NF-kappaB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a. Immunity 21: 203-213.
108. Su H, Bidere N, Lenardo M (2004) Another fork in the road: Foxo3a regulates NF-kappaB activation. Immunity 21: 133-134.
109. Pollard KS, Salama SR, Lambert N, Lambot MA, Coppens S, et al. (2006) An RNA gene expressed during cortical development evolved rapidly in humans. Nature 443: 167-172.
110. Panteri R, Mey J, Zhelyaznik N, D'Altocolle A, Del Fa A, et al. (2006) Reelin is transiently expressed in the peripheral nerve during development and is upregulated following nerve crush. Mol Cell Neurosci 32: 133-142.
111. Pollard KS, Salama SR, King B, Kern AD, Dreszer T, et al. (2006) Forces shaping the fastest evolving regions in the human genome. PLoS Genet 2: e168.
112. Pollard KS (2009) What makes us human? Sci Am 300: 44-49.
113. Nakamura Y, Takahashi N, Kakegawa E, Yoshida K, Ito Y, et al. (2008) The GAS5 (growth arrest-specific transcript 5) gene fuses to BCL6 as a result of t(1;3)(q25;q27) in a patient with B-cell lymphoma. Cancer Genet Cytogenet 182: 144-149.
114. Tanaka R, Satoh H, Moriyama M, Satoh K, Morishita Y, et al. (2000) Intronic U50 small-nucleolar-RNA (snoRNA) host gene of no protein-coding potential is mapped at the chromosome breakpoint t(3;6)(q27;q15) of human B-cell lymphoma. Genes Cells 5: 277-287.
115. Hirst CL, Pace A, Pickersgill TP, Jones R, McLean BN, et al. (2008) Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 255: 231-238.
116. Jones JL, Coles AJ (2008) Campath-1H treatment of multiple sclerosis. Neurodegener Dis 5: 27-31.
117. Muraro PA, Bielekova B (2007) Emerging therapies for multiple sclerosis. Neurotherapeutics 4: 676-692.
118. Simpson BS, Coles AJ (2007) Rationale for cytotoxic monoclonal antibodies in MS. Int MS J 14: 48-56.
119. Coles AJ, Wing M, Smith S, Coraddu F, Greer S, et al. (1999) Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354: 1691-1695.
120. Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, et al. (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46: 296-304.
121. Coles AJ, Wing MG, Compston DA (1998) Disease activity and the immune set in multiple sclerosis: blood markers for immunotherapy. Mult Scler 4: 232-238.
122. Moreau T, Coles A, Wing M, Thorpe J, Miller D, et al. (1996) CAMPATH-IH in multiple sclerosis. Mult Scler 1: 357-365.
123. Moreau T, Thorpe J, Miller D, Moseley I, Hale G, et al. (1994) Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 344: 298-301.
124. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, et al. (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359: 1786-1801.
125. Rosenberg HF (2008) RNase A ribonucleases and host defense: an evolving story. J Leukoc Biol 83: 1079-1087.
126. Rosenberg HF (2008) Eosinophil-derived neurotoxin/RNase 2: connecting the past, the present and the future. Curr Pharm Biotechnol 9: 135-140.
127. Durack DT, Ackerman SJ, Loegering DA, Gleich GJ (1981) Purification of human eosinophil-derived neurotoxin. Proc Natl Acad Sci U S A 78: 5165-5169.
128. Patwardhan S, Gashler A, Siegel MG, Chang LC, Joseph LJ, et al. (1991) EGR3, a novel member of the Egr family of genes encoding immediate-early transcription factors. Oncogene 6: 917-928.
129. Crosby SD, Veile RA, Donis-Keller H, Baraban JM, Bhat RV, et al. (1992) Neural-specific expression, genomic structure, and chromosomal localization of the gene encoding the zinc-finger transcription factor NGFI-C. Proc Natl Acad Sci U S A 89: 4739-4743.
130. Xi H, Kersh GJ (2004) Early growth response gene 3 regulates thymocyte proliferation during the transition from CD4-CD8- to CD4+CD8+. J Immunol 172: 964-971.
131. Safford M, Collins S, Lutz MA, Allen A, Huang CT, et al. (2005) Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol 6: 472-480.
132. Collins S, Lutz MA, Zarek PE, Anders RA, Kersh GJ, et al. (2008) Opposing regulation of T cell function by Egr-1/NAB2 and Egr-2/Egr-3. Eur J Immunol 38: 528-536.
133. Zheng Y, Zha Y, Gajewski TF (2008) Molecular regulation of T-cell anergy. EMBO Rep 9: 50-55.
134. Fukuyama T, Kasper LH, Boussouar F, Jeevan T, van Deursen J, et al. (2009) Histone acetyltransferase CBP is vital to demarcate conventional and innate CD8+ T-cell development. Mol Cell Biol 29: 3894-3904.
135. Jones EA, Jang SW, Mager GM, Chang LW, Srinivasan R, et al. (2007) Interactions of Sox10 and Egr2 in myelin gene regulation. Neuron Glia Biol 3: 377-387.
136. Jessen KR, Mirsky R (2008) Negative regulation of myelination: relevance for development, injury, and demyelinating disease. Glia 56: 1552-1565.
137. Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton SM, et al. (2009) Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet 5: e1000369.
138. Kida E, Palminiello S, Golabek AA, Walus M, Wierzba-Bobrowicz T, et al. (2006) Carbonic anhydrase II in the developing and adult human brain. J Neuropathol Exp Neurol 65: 664-674.
139. Cammer W (1998) Glial-cell cultures from brains of carbonic anhydrase II- deficient mutant mice: delay in oligodendrocyte maturation. Neurochem Res 23: 407-412.
140. Cammer W, Zhang H, Tansey FA (1995) Effects of carbonic anhydrase II (CAII) deficiency on CNS structure and function in the myelin-deficient CAII- deficient double mutant mouse. J Neurosci Res 40: 451-457.
141. Sigurdsson S, Goring HH, Kristjansdottir G, Milani L, Nordmark G, et al. (2008) Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 17: 872-881.
142. Awano T, Johnson GS, Wade CM, Katz ML, Johnson GC, et al. (2009) Genome-wide association analysis reveals a SOD1 mutation in canine degenerative myelopathy that resembles amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 106: 2794-2799.
143. Gerstner B, DeSilva TM, Genz K, Armstrong A, Brehmer F, et al. (2008) Hyperoxia causes maturation-dependent cell death in the developing white matter. J Neurosci 28: 1236-1245.
144. Avossa D, Grandolfo M, Mazzarol F, Zatta M, Ballerini L (2006) Early signs of motoneuron vulnerability in a disease model system: Characterization of transverse slice cultures of spinal cord isolated from embryonic ALS mice. Neuroscience 138: 1179-1194.
145. Sasaki S, Warita H, Abe K, Iwata M (2004) Slow component of axonal transport is impaired in the proximal axon of transgenic mice with a G93A mutant SOD1 gene. Acta Neuropathol 107: 452-460.
146. Tajouri L, Mellick AS, Ashton KJ, Tannenberg AE, Nagra RM, et al. (2003) Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res Mol Brain Res 119: 170-183.
147. Ince PG, Tomkins J, Slade JY, Thatcher NM, Shaw PJ (1998) Amyotrophic lateral sclerosis associated with genetic abnormalities in the gene encoding Cu/ Zn superoxide dismutase: molecular pathology of five new cases, and comparison with previous reports and 73 sporadic cases of ALS. J Neuropathol Exp Neurol 57: 895-904.
148. Azzouz M, Leclerc N, Gurney M, Warter JM, Poindron P, et al. (1997) Progressive motor neuron impairment in an animal model of familial amyotrophic lateral sclerosis. Muscle Nerve 20: 45-51.
149. Guy J (2008) Optic nerve degeneration in experimental autoimmune encephalomyelitis. Ophthalmic Res 40: 212-216.
150. Roth TM, Ramamurthy P, Ebisu F, Lisak RP, Bealmear BM, et al. (2007) A mouse embryonic stem cell model of Schwann cell differentiation for studies of the role of neurofibromatosis type 1 in Schwann cell development and tumor formation. Glia 55: 1123-1133.
151. Rosenbaum T, Kim HA, Boissy YL, Ling B, Ratner N (1999) Neurofibromin, the neurofibromatosis type 1 Ras-GAP, is required for appropriate P0 expression and myelination. Ann N Y Acad Sci 883: 203-214.
152. Gutmann DH, Tennekoon GI, Cole JL, Collins FS, Rutkowski JL (1993) Modulation of the neurofibromatosis type 1 gene product, neurofibromin, during Schwann cell differentiation. J Neurosci Res 36: 216-223.
153. Habib AA, Marton LS, Allwardt B, Gulcher JR, Mikol DD, et al. (1998) Expression of the oligodendrocyte-myelin glycoprotein by neurons in the mouse central nervous system. J Neurochem 70: 1704-1711.
154. Kim HA, Ling B, Ratner N (1997) Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase. Mol Cell Biol 17: 862-872.
155. Perini P, Gallo P (2001) The range of multiple sclerosis associated with neurofibromatosis type 1. J Neurol Neurosurg Psychiatry 71: 679-681.
156. Ferner RE, Hughes RA, Johnson MR (1995) Neurofibromatosis 1 and multiple sclerosis. J Neurol Neurosurg Psychiatry 58: 582-585.
157. Habib AA, Gulcher JR, Hognason T, Zheng L, Stefansson K (1998) The OMgp gene, a second growth suppressor within the NF1 gene. Oncogene 16: 1525-1531.
158. Wang M, Windgassen D, Papoutsakis ET (2008) Comparative analysis of transcriptional profiling of CD3+, CD4+ and CD8+ T cells identifies novel immune response players in T-cell activation. BMC Genomics 9: 225.
159. Fischer A, de Saint Basile G, Le Deist F (2005) CD3 deficiencies. Curr Opin Allergy Clin Immunol 5: 491-495.
160. de Saint Basile G, Geissmann F, Flori E, Uring-Lambert B, Soudais C, et al. (2004) Severe combined immunodeficiency caused by deficiency in either the delta or the epsilon subunit of CD3. J Clin Invest 114: 1512-1517.
161. van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD, et al. (2008) Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med 45: 1729-1737.
162. Plumb J, McQuaid S, Cross AK, Surr J, Haddock G, et al. (2006) Upregulation of ADAM-17 expression in active lesions in multiple sclerosis. Mult Scler 12: 375-385.
163. Reimand J, Kull M, Peterson H, Hansen J, Vilo J (2007) g:Profiler-a web- based toolset for functional profiling of gene lists from large-scale experiments. Nucleic Acids Res 35: W193-200.
164. Steinman L (2001) Multiple sclerosis: a two-stage disease. Nat Immunol 2: 762-764.
165. Wucherpfennig KW, Catz I, Hausmann S, Strominger JL, Steinman L, et al. (1997) Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J Clin Invest 100: 1114-1122.
166. Olson JK, Croxford JL, Calenoff MA, Dal Canto MC, Miller SD (2001) A virus-induced molecular mimicry model of multiple sclerosis. The Journal of Clinical Investigation 108: 311-318.
167. Sibley WA, Bamford CR, Clark K (1985) CLINICAL VIRAL-INFECTIONS AND MULTIPLE-SCLEROSIS. Lancet 1: 1313-1315.
168. Andersen O, Lygner PE, Bergstrom T, Andersson M, Vahlne A (1993) VIRAL-INFECTIONS TRIGGER MULTIPLE-SCLEROSIS RELAPSES - A PROSPECTIVE SEROEPIDEMIOLOGICAL STUDY. Journal of Neurology 240: 417-422.
169. Hillel SPanitch (1994) Influence of infection on exacerbations of multiple sclerosis. Annals of Neurology 36: S25-S28.
170. Edwards S, Zvartau M, Clarke H, Irving W, Blumhardt LD (1998) Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. J Neurol Neurosurg Psychiatry 64: 736-741.
171. Buljevac D, Flach HZ, Hop WCJ, Hijdra D, Laman JD, et al. (2002) Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125: 952-960.
172. Inostroza-Ponta M, Berretta R, Mendes A, Moscato P (2006) An automatic graph layout procedure to visualize correlated data. In: IFIP International Federation for Information Processing, Volume 217, Artificial Intelligence in Theory and Practice. Bramer M, ed. Boston: Boston. pp 179-188.
173. Inostroza-Ponta M, Mendes A, Berretta R, Moscato P (2007) An Integrated QAP-Based Approach to Visualize Patterns of Gene Expression Similarity. LECTURE NOTES IN COMPUTER SCIENCE.
174. Shimada M, Komatsu K (2009) Emerging connection between centrosome and DNA repair machinery. J Radiat Res (Tokyo) 50: 295-301.
175. Bond J, Roberts E, Mochida GH, Hampshire DJ, Scott S, et al. (2002) ASPM is a major determinant of cerebral cortical size. Nat Genet 32: 316-320.
176. Ali F, Meier R (2008) Positive selection in ASPM is correlated with cerebral cortex evolution across primates but not with whole-brain size. Mol Biol Evol 25: 2247-2250.
177. Fish JL, Dehay C, Kennedy H, Huttner WB (2008) Making bigger brains-the evolution of neural-progenitor-cell division. J Cell Sci 121: 2783-2793.
178. Dobson-Stone C, Gatt JM, Kuan SA, Grieve SM, Gordon E, et al. (2007) Investigation of MCPH1 G37995C and ASPM A44871G polymorphisms and brain size in a healthy cohort. Neuroimage 37: 394-400.
179. Timpson N, Heron J, Smith GD, Enard W (2007) Comment on papers by Evans et al. and Mekel-Bobrov et al. on Evidence for Positive Selection of MCPH1 and ASPM. Science 317: 1036; author reply 1036.
180. Dediu D (2008) The role of genetic biases in shaping the correlations between languages and genes. J Theor Biol 254: 400-407.
181. Dediu D, Ladd DR (2007) Linguistic tone is related to the population frequency of the adaptive haplogroups of two brain size genes, ASPM and Microcephalin. Proc Natl Acad Sci U S A 104: 10944-10949.
182. Frost P (2008) The spread of alphabetical writing may have favored the latest variant of the ASPM gene. Med Hypotheses 70: 17-20.
183. Muhammad F, Mahmood Baig S, Hansen L, Sajid Hussain M, Anjum Inayat I, et al. (2009) Compound heterozygous ASPM mutations in Pakistani MCPH families. Am J Med Genet A 149A: 926-930.
184. Bishop DV (2009) Genes, cognition, and communication: insights from neurodevelopmental disorders. Ann N Y Acad Sci 1156: 1-18.
185. Saadi A, Borck G, Boddaert N, Chekkour MC, Imessaoudene B, et al. (2009) Compound heterozygous ASPM mutations associated with microcephaly and simplified cortical gyration in a consanguineous Algerian family. Eur J Med Genet 52: 180-184.
186. Kumar A, Girimaji SC, Duvvari MR, Blanton SH (2009) Mutations in STIL, encoding a pericentriolar and centrosomal protein, cause primary microceph- aly. Am J Hum Genet 84: 286-290.
187. Nicholas AK, Swanson EA, Cox JJ, Karbani G, Malik S, et al. (2009) The molecular landscape of ASPM mutations in primary microcephaly. J Med Genet 46: 249-253.
188. Desir J, Cassart M, David P, Van Bogaert P, Abramowicz M (2008) Primary microcephaly with ASPM mutation shows simplified cortical gyration with antero-posterior gradient pre- and post-natally. Am J Med Genet A 146A: 1439-1443.
189. Morgenthaler NG, Seissler J, Achenbach P, Glawe D, Payton M, et al. (1997) Antibodies to the tyrosine phosphatase-like protein IA-2 are highly associated with IDDM, but not with autoimmune endocrine diseases or stiff man syndrome. Autoimmunity 25: 203-211.
190. Schmidli RS, Colman PG, Cui L, Yu WP, Kewming K, et al. (1998) Antibodies to the protein tyrosine phosphatases IAR and IA-2 are associated with progression to insulin-dependent diabetes (IDDM) in first-degree relatives at- risk for IDDM. Autoimmunity 28: 15-23.
191. Miao D, Yu L, Eisenbarth GS (2007) Role of autoantibodies in type 1 diabetes. Front Biosci 12: 1889-1898.
192. Williams AJ, Aitken RJ, Chandler MA, Gillespie KM, Lampasona V, et al. (2008) Autoantibodies to islet antigen-2 are associated with HLA-DRB1*07 and DRB1*09 haplotypes as well as DRB1*04 at onset of type 1 diabetes: the possible role of HLA-DQA in autoimmunity to IA-2. Diabetologia 51: 1444-1448.
193. Lan MS, Wasserfall C, Maclaren NK, Notkins AL (1996) IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 93: 6367-6370.
194. Lu J, Li Q, Xie H, Chen ZJ, Borovitskaya AE, et al. (1996) Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Proc Natl Acad Sci U S A 93: 2307-2311.
195. Kim SM, Theilig F, Qin Y, Cai T, Mizel D, et al. (2009) Dense-core vesicle proteins IA-2 and IA-2{beta} affect renin synthesis and secretion through the {beta}-adrenergic pathway. Am J Physiol Renal Physiol 296: F382-389.
196. Shimizu S, Saito N, Kubosaki A, SungWook S, Takeyama N, et al. (2001) Developmental expression and localization of IA-2 mRNA in mouse neuroendocrine tissues. Biochem Biophys Res Commun 288: 165-171.
197. Saeki K, Zhu M, Kubosaki A, Xie J, Lan MS, et al. (2002) Targeted disruption of the protein tyrosine phosphatase-like molecule IA-2 results in alterations in glucose tolerance tests and insulin secretion. Diabetes 51: 1842-1850.
198. Roifman CM (2004) CD3 delta immunodeficiency. Curr Opin Allergy Clin Immunol 4: 479-484.
199. Grunebaum E, Sharfe N, Roifman CM (2006) Human T cell immunodefi- ciency: when signal transduction goes wrong. Immunol Res 35: 117-126.
200. Akl H, Badran B, Dobirta G, Manfouo-Foutsop G, Moschitta M, et al. (2007) Progressive loss of CD3 expression after HTLV-I infection results from chromatin remodeling affecting all the CD3 genes and persists despite early viral genes silencing. Virol J 4: 85.
201. Fernandez-Malave E, Wang N, Pulgar M, Schamel WW, Alarcon B, et al. (2006) Overlapping functions of human CD3delta and mouse CD3gamma in alphabeta T-cell development revealed in a humanized CD3gamma-mouse. Blood 108: 3420-3427.
202. Takada H, Nomura A, Roifman CM, Hara T (2005) Severe combined immunodeficiency caused by a splicing abnormality of the CD3delta gene. Eur J Pediatr 164: 311-314.
203. Roifman CM (2005) Studies of patients' thymi aid in the discovery and characterization of immunodeficiency in humans. Immunol Rev 203: 143-155.
204. Pan Q, Gollapudi AS, Dave VP (2004) Biochemical evidence for the presence of a single CD3delta and CD3gamma chain in the surface T cell receptor/CD3 complex. J Biol Chem 279: 51068-51074.
205. Oh SJ, Cho SB, Park SH, Piao CZ, Kwon SM, et al. (2008) Cell cycle and immune-related processes are significantly altered in chronic GVHD. Bone Marrow Transplant 41: 1047-1057.
206. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI (2005) Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum 52: 1534-1544.
207. Doucey MA, Goffin L, Naeher D, Michielin O, Baumgartner P, et al. (2003) CD3 delta establishes a functional link between the T cell receptor and CD8. J Biol Chem 278: 3257-3264.
208. Hayes SM, Shores EW, Love PE (2003) An architectural perspective on signaling by the pre-, alphabeta and gammadelta T cell receptors. Immunol Rev 191: 28-37.
209. Schmitt SG, Aftab U, Jiang C, Redenti S, Klassen H, et al. (2009) Molecular Characterization of Human Retinal Progenitor Cells. Invest Ophthalmol Vis Sci.
210. Huang M, Itahana K, Zhang Y, Mitchell BS (2009) Depletion of guanine nucleotides leads to the Mdm2-dependent proteasomal degradation of nucleostemin. Cancer Res 69: 3004-3012.
211. Leonard BW, Mastroeni D, Grover A, Liu Q, Yang K, et al. (2009) Subventricular zone neural progenitors from rapid brain autopsies of elderly subjects with and without neurodegenerative disease. J Comp Neurol 515: 269-294.
212. Scott LJ, Muglia P, Kong XQ, Guan W, Flickinger M, et al. (2009) Genome- wide association and meta-analysis of bipolar disorder in individuals of European ancestry. Proc Natl Acad Sci U S A 106: 7501-7506.
213. Dai MS, Sun XX, Lu H (2008) Aberrant expression of nucleostemin activates p53 and induces cell cycle arrest via inhibition of MDM2. Mol Cell Biol 28: 4365-4376.
214. Seto E, Shi Y, Shenk T (1991) YY1 is an initiator sequence-binding protein that directs and activates transcription in vitro. Nature 354: 241-245.
215. Xi H, Yu Y, Fu Y, Foley J, Halees A, et al. (2007) Analysis of overrepresented motifs in human core promoters reveals dual regulatory roles of YY1. Genome Res 17: 798-806.
216. Perry RP (2005) The architecture of mammalian ribosomal protein promoters. BMC Evol Biol 5: 15.
217. Castellano G, Torrisi E, Ligresti G, Malaponte G, Militello L, et al. (2009) The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle 8: 1367-1372.
218. Wu S, Murai S, Kataoka K, Miyagishi M (2008) Yin Yang 1 induces transcriptional activity of p73 through cooperation with E2F1. Biochem Biophys Res Commun 365: 75-81.
219. Wu S, Murai S, Kataoka K, Miyagishi M (2007) Cooperative regulation of p73 promoter by Yin Yang 1 and E2F1. Nucleic Acids Symp Ser (Oxf). pp 347-348.
220. Hiromura M, Choi CH, Sabourin NA, Jones H, Bachvarov D, et al. (2003) YY1 is regulated by O-linked N-acetylglucosaminylation (O-glcNAcylation). J Biol Chem 278: 14046-14052.
221. Guo J, Casolaro V, Seto E, Yang WM, Chang C, et al. (2001) Yin-Yang 1 activates interleukin-4 gene expression in T cells. J Biol Chem 276: 48871-48878.
222. Guo J, Lin X, Williams MA, Hamid Q, Georas SN (2008) Yin-Yang 1 regulates effector cytokine gene expression and T(H)2 immune responses. J Allergy Clin Immunol 122: 195-201, 201 e191-195.
223. Tone Y, Kojima Y, Furuuchi K, Brady M, Yashiro-Ohtani Y, et al. (2007) OX40 gene expression is up-regulated by chromatin remodeling in its promoter region containing Sp1/Sp3, YY1, and NF-kappa B binding sites. J Immunol 179: 1760-1767.
224. Oh J, Broyles SS (2005) Host cell nuclear proteins are recruited to cytoplasmic vaccinia virus replication complexes. J Virol 79: 12852-12860.
225. Ji HB, Gupta A, Okamoto S, Blum MD, Tan L, et al. (2002) T cell-specific expression of the murine CD3delta promoter. J Biol Chem 277: 47898-47906.
226. Montalvo EA, Cottam M, Hill S, Wang YJ (1995) YY1 binds to and regulates cis-acting negative elements in the Epstein-Barr virus BZLF1 promoter. J Virol 69: 4158-4165.
227. Zalani S, Coppage A, Holley-Guthrie E, Kenney S (1997) The cellular YY1 transcription factor binds a cis-acting, negatively regulating element in the Epstein-Barr virus BRLF1 promoter. J Virol 71: 3268-3274.
228. He Y, Casaccia-Bonnefil P (2008) The Yin and Yang of YY1 in the nervous system. J Neurochem 106: 1493-1502.
229. Berndt JA, Kim JG, Tosic M, Kim C, Hudson LD (2001) The transcriptional regulator Yin Yang 1 activates the myelin PLP gene. J Neurochem 77: 935-942.
230. Ai W, Narahari J, Roman A (2000) Yin yang 1 negatively regulates the differentiation-specific E1 promoter of human papillomavirus type 6. J Virol 74: 5198-5205.
231. Pande S, Jain N, Prusty BK, Bhambhani S, Gupta S, et al. (2008) Human papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in biopsy samples from cervical cancer patients in north India. J Clin Microbiol 46: 1060-1066.
232. Knutson BA, Oh J, Broyles SS (2009) Downregulation of vaccinia virus intermediate and late promoters by host transcription factor YY1. J Gen Virol.
233. Khalil MI, Hay J, Ruyechan WT (2008) Cellular transcription factors Sp1 and Sp3 suppress varicella-zoster virus origin-dependent DNA replication. J Virol 82: 11723-11733.
234. Le May N, Mansuroglu Z, Leger P, Josse T, Blot G, et al. (2008) A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. PLoS Pathog 4: e13.
235. Mai RT, Yeh TS, Kao CF, Sun SK, Huang HH, et al. (2006) Hepatitis C virus core protein recruits nucleolar phosphoprotein B23 and coactivator p300 to relieve the repression effect of transcriptional factor YY1 on B23 gene expression. Oncogene 25: 448-462.
236. Liu H, Schmidt-Supprian M, Shi Y, Hobeika E, Barteneva N, et al. (2007) Yin Yang 1 is a critical regulator of B-cell development. Genes Dev 21: 1179-1189.
237. Erkeland SJ, Valkhof M, Heijmans-Antonissen C, Delwel R, Valk PJ, et al. (2003) The gene encoding the transcriptional regulator Yin Yang 1 (YY1) is a myeloid transforming gene interfering with neutrophilic differentiation. Blood 101: 1111-1117.
238. He Y, Sandoval J, Casaccia-Bonnefil P (2007) Events at the transition between cell cycle exit and oligodendrocyte progenitor differentiation: the role of HDAC and YY1. Neuron Glia Biol 3: 221-231.
239. He Y, Dupree J, Wang J, Sandoval J, Li J, et al. (2007) The transcription factor Yin Yang 1 is essential for oligodendrocyte progenitor differentiation. Neuron 55: 217-230.
240. Topilko P, Schneider-Maunoury S, Levi G, Baron-Van Evercooren A, Chennoufi AB, et al. (1994) Krox-20 controls myelination in the peripheral nervous system. Nature 371: 796-799.
241. Bhatheja K, Field J (2006) Schwann cells: origins and role in axonal maintenance and regeneration. Int J Biochem Cell Biol 38: 1995-1999.
242. Murphy P, Topilko P, Schneider-Maunoury S, Seitanidou T, Baron-Van Evercooren A, et al. (1996) The regulation of Krox-20 expression reveals important steps in the control of peripheral glial cell development. Development 122: 2847-2857.
243. Scherer SS (1997) The biology and pathobiology of Schwann cells. Curr Opin Neurol 10: 386-397.
244. Schumacher M, Guennoun R, Mercier G, Desarnaud F, Lacor P, et al. (2001) Progesterone synthesis and myelin formation in peripheral nerves. Brain Res Brain Res Rev 37: 343-359.
245. Guennoun R, Benmessahel Y, Delespierre B, Gouezou M, Rajkowski KM, et al. (2001) Progesterone stimulates Krox-20 gene expression in Schwann cells. Brain Res Mol Brain Res 90: 75-82.
246. Mercier G, Turque N, Schumacher M (2001) Early activation of transcription factor expression in Schwann cells by progesterone. Brain Res Mol Brain Res 97: 137-148.
247. Magnaghi V, Ballabio M, Roglio I, Melcangi RC (2007) Progesterone derivatives increase expression of Krox-20 and Sox-10 in rat Schwann cells. J Mol Neurosci 31: 149-157.
248. Mirsky R, Woodhoo A, Parkinson DB, Arthur-Farraj P, Bhaskaran A, et al. (2008) Novel signals controlling embryonic Schwann cell development, myelination and dedifferentiation. J Peripher Nerv Syst 13: 122-135.
249. Jessen KR, Mirsky R (1998) Origin and early development of Schwann cells. Microsc Res Tech 41: 393-402.
250. Wakatsuki S, Yumoto N, Komatsu K, Araki T, Sehara-Fujisawa A (2009) Roles of meltrin-beta/ADAM19 in progression of Schwann cell differentiation and myelination during sciatic nerve regeneration. J Biol Chem 284: 2957-2966.
251. Parkinson DB, Bhaskaran A, Arthur-Farraj P, Noon LA, Woodhoo A, et al. (2008) c-Jun is a negative regulator of myelination. J Cell Biol 181: 625-637.
252. Parkinson DB, Bhaskaran A, Droggiti A, Dickinson S, D'Antonio M, et al. (2004) Krox-20 inhibits Jun-NH2-terminal kinase/c-Jun to control Schwann cell proliferation and death. J Cell Biol 164: 385-394.
253. Salzer JL (2008) Switching myelination on and off. J Cell Biol 181: 575-577.
254. Topilko P, Levi G, Merlo G, Mantero S, Desmarquet C, et al. (1997) Differential regulation of the zinc finger genes Krox-20 and Krox-24 (Egr-1) suggests antagonistic roles in Schwann cells. J Neurosci Res 50: 702-712.
255. Dugas JC, Tai YC, Speed TP, Ngai J, Barres BA (2006) Functional genomic analysis of oligodendrocyte differentiation. J Neurosci 26: 10967-10983.
256. Larocque D, Fragoso G, Huang J, Mushynski WE, Loignon M, et al. (2009) The QKI-6 and QKI-7 RNA binding proteins block proliferation and promote Schwann cell myelination. PLoS One 4: e5867.
257. Sock E, Leger H, Kuhlbrodt K, Schreiber J, Enderich J, et al. (1997) Expression of Krox proteins during differentiation of the O-2A progenitor cell line CG-4. J Neurochem 68: 1911-1919.
258. Harris JE, Bishop KD, Phillips NE, Mordes JP, Greiner DL, et al. (2004) Early growth response gene-2, a zinc-finger transcription factor, is required for full induction of clonal anergy in CD4+ T cells. J Immunol 173: 7331-7338.
259. Okamura T, Fujio K, Shibuya M, Sumitomo S, Shoda H, et al. (2009) CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2. Proc Natl Acad Sci U S A 106: 13974-13979.
260. Hsiao HW, Liu WH, Wang CJ, Lo YH, Wu YH, et al. (2009) Deltex1 is a target of the transcription factor NFAT that promotes T cell anergy. Immunity 31: 72-83.
261. Zhu B, Symonds AL, Martin JE, Kioussis D, Wraith DC, et al. (2008) Early growth response gene 2 (Egr-2) controls the self-tolerance of T cells and prevents the development of lupuslike autoimmune disease. J Exp Med 205: 2295-2307.
262. Mittelstadt PR, Ashwell JD (1999) Role of Egr-2 in up-regulation of Fas ligand in normal T cells and aberrant double-negative lpr and gld T cells. J Biol Chem 274: 3222-3227.
263. Kramer B, Meichle A, Hensel G, Charnay P, Kronke M (1994) Character- ization of an Krox-24/Egr-1-responsive element in the human tumor necrosis factor promoter. Biochim Biophys Acta 1219: 413-421.
264. Cron RQ, Bandyopadhyay R, Genin A, Brunner M, Kersh GJ, et al. (2006) Early growth response-1 is required for CD154 transcription. J Immunol 176: 811-818.
265. Chang X, Chen L, Wen J, Godfrey VL, Qiao G, et al. (2006) Foxp3 controls autoreactive T cell activation through transcriptional regulation of early growth response genes and E3 ubiquitin ligase genes, independently of thymic selection. Clin Immunol 121: 274-285.
266. Wieland GD, Nehmann N, Muller D, Eibel H, Siebenlist U, et al. (2005) Early growth response proteins EGR-4 and EGR-3 interact with immune inflammatory mediators NF-kappaB p50 and p65. J Cell Sci 118: 3203-3212.
267. Decker EL, Nehmann N, Kampen E, Eibel H, Zipfel PF, et al. (2003) Early growth response proteins (EGR) and nuclear factors of activated T cells (NFAT) form heterodimers and regulate proinflammatory cytokine gene expression. Nucleic Acids Res 31: 911-921.
268. Mullin M, Lightfoot K, Clarke R, Miller M, Lahesmaa R, et al. (2007) The RhoA transcriptional program in pre-T cells. FEBS Lett 581: 4309-4317.
269. Taghon T, Yui MA, Pant R, Diamond RA, Rothenberg EV (2006) Developmental and molecular characterization of emerging beta- and gammadelta-selected pre-T cells in the adult mouse thymus. Immunity 24: 53-64.
270. Seiwa C, Kojima-Aikawa K, Matsumoto I, Asou H (2002) CNS myelinogenesis in vitro: myelin basic protein deficient shiverer oligodendrocytes. J Neurosci Res 69: 305-317.
271. Petro TM (2005) ERK-MAP-kinases differentially regulate expression of IL-23 p19 compared with p40 and IFN-beta in Theiler's virus-infected RAW264.7 cells. Immunol Lett 97: 47-53.
272. Samten B, Townsend JC, Weis SE, Bhoumik A, Klucar P, et al. (2008) CREB, ATF, and AP-1 transcription factors regulate IFN-gamma secretion by human T cells in response to mycobacterial antigen. J Immunol 181: 2056-2064.
273. Stolt CC, Schlierf A, Lommes P, Hillgartner S, Werner T, et al. (2006) SoxD proteins influence multiple stages of oligodendrocyte development and modulate SoxE protein function. Dev Cell 11: 697-709.
274. Yui MA, Rothenberg EV (2004) Deranged early T cell development in immunodeficient strains of nonobese diabetic mice. J Immunol 173: 5381-5391.
275. Georgescu C, Longabaugh WJ, Scripture-Adams DD, David-Fung ES, Yui MA, et al. (2008) A gene regulatory network armature for T lymphocyte specification. Proc Natl Acad Sci U S A 105: 20100-20105.
276. David-Fung ES, Butler R, Buzi G, Yui MA, Diamond RA, et al. (2009) Transcription factor expression dynamics of early T-lymphocyte specification and commitment. Dev Biol 325: 444-467.
277. Rothenberg EV, Pant R (2004) Origins of lymphocyte developmental programs: transcription factor evidence. Semin Immunol 16: 227-238.
278. Rothenberg EV (2009) Decision by committee: new light on the CD4/CD8- lineage choice. Immunol Cell Biol 87: 109-112.
279. Rothenberg EV, Moore JE, Yui MA (2008) Launching the T-cell-lineage developmental programme. Nat Rev Immunol 8: 9-21.
280. Rothenberg EV, Scripture-Adams DD (2008) Competition and collaboration: GATA-3, PU.1, and Notch signaling in early T-cell fate determination. Semin Immunol 20: 236-246.
281. Rothenberg EV (2002) T-lineage specification and commitment: a gene regulation perspective. Semin Immunol 14: 431-440.
282. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the ''McDonald Criteria''. Ann Neurol 58: 840-846.
283. Thompson AJ, Montalban X, Barkhof F, Brochet B, Filippi M, et al. (2000) Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 47: 831-835.
284. (1998) Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 352: 1491-1497.
285. Moscato P, Mendes A, Berretta R (2007) Benchmarking a memetic algorithm for ordering microarray data. Biosystems 88: 56-75.